EmpNia™, a medical device company focused on advancing cancer treatment through precision technologies, has received clearance from the U.S. Food and Drug Administration (FDA) to market its latest innovation, eMotus™, across hospitals and cancer centres in the United States.
Respiratory motion during image-guided radiation therapy (IGRT) continues to pose a challenge for clinicians.
Many current systems are complex to operate, disrupt clinical routines, are not suitable for all patients, and often require significant investment in new equipment.
eMotus has been developed to address these issues through a straightforward and practical approach. The system includes a single-use disposable sensor pad paired with intuitive software.
It can be set up within minutes, installed in a matter of hours, and is designed to work with all existing imaging and treatment equipment.
This universal compatibility helps care providers adopt advanced motion management without major infrastructure changes or high costs.
The system supports all patient types and aims to simplify how respiratory motion is monitored during both imaging and radiation treatment.
By reducing the need for specialised setups and avoiding the complexity of traditional systems, eMotus helps clinical teams maintain focus on patient care rather than equipment management.
eMotus is intended for use by professionals in radiation oncology who need to monitor and manage respiratory motion in patients undergoing image-guided radiation therapy.
